Mayo Clinic continues to be the leader in US News Rankings. Continues to have the most specialties ranked 1st in the nation. I have been Mayo Clinic for 29 years, including 25 years as faculty— Proud to work at this great institution.

Patients with PNH or Aplastic Anemia: Did you miss this webinar? The recording is ready for you now! Get the updates from the most recent ASH meeting on research and treatment: aamds.org/webinar/ash-20… #aplasticanemia #pnh #marrowfailure

#MSP #Airport land of #messi #argentina

Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes | NEJM Evidence || ⁦Tapan Kadia⁩ ⁦Naveen Pemmaraju, MD⁩ ⁦Lucia Masarova, MD⁩ #MPNSM ⁦MD Anderson Cancer Center⁩ #endcancer ⁦NEJM Evidence⁩ evidence.nejm.org/doi/full/10.10…

Mayo Clinic hematologist oncologist Dr. @gregnowakowski discusses the accelerated approval of bispecific antibody epcoritamab-bysp in #FollicularLymphoma, touching on key trial data and remaining unmet needs. Via OncLive.com bit.ly/3ycnRqo

Honored to co-lead an educational conference featuring outstanding and great experts & colleagues Talha Badar Madiha Iqbal MD Muhamad Alhaj Moustafa, MD, MS Mohamed Kharfan-Dabaja, MD, MBA Hemant S. Murthy MD Jeremy Jones Ricardo Parrondo, MD Jason Starr Hetty Carraway Muhamad Alhaj Moustafa, MD, MS Elizabeth Plimack MD Smitha Krishnamurthi Pamela Kunz, MD, FASCO

FDA Extends PDUFA Date for Revumenib in KMT2A-Rearranged Acute Leukemia onclive.com/view/fda-exten… via @onclive

#CHIP meta analysis 👍 ⭐️ ⬆️ mortality ⭐️ ⬆️ CAD HF but not cardiac death ⭐️ ⬆️ CVA ⭐️ ⬆️ kidney dz ⭐️ ⬆️ HEM-Meyloid ⭐️ ⬆️ Lung CA ⭐️ ⬆️ severe covid ⭐️ DNMT3A neutral Blood Advances Clonal hematopoiesis of indeterminate potential as a prognostic factor: a

Look forward for engaging discussion next week. So many good questions come up during the Q&A session. #CML #CLL

Starting Now: Myelodysplastic Syndrome Moderated by: Tapan Kadia #DAVAHeme

📢Results of our multicenter study! Krishna Gundabolu MBBS; MS Stephanie Lee, MD Taiga Nishihori, MD ascopubs.org/doi/10.1200/JC… UNMC Heme Onc UNMC Department of Internal Medicine Research @ UNMC

👉🏽 Check out our recent paper on the outcomes of N/D patients with AML having WBC >100x10e9 at presentation ✅63% had FLT3 mut ✅8 week mortality of 13%: all in pts >65 years ✅Age>65, LDH>2000, high lactates, adverse CTG prognostic for OS Fadi Haddad, MD Hagop Kantarjian,MD Tapan Kadia

#Ivosidenib in r/r #MDS with #IDH1m ⭐️ 38.9% CR+PR ⭐️ 83.3% ORR ⭐️ mOS 35.7m ⭐️ 10.5% DS 👀 Blood Advances Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome ashpublications.org/bloodadvances/…

Look forward to talk about high grade #MDS and transformation into #sAML ⁦The Leukemia & Lymphoma Society⁩ Treating Myelodysplastic Syndromes Transformation to Acute Myeloid Leukemia | Leukemia and Lymphoma Society lls.org/event/treating…

Outcome of #NPM1m #AML ⭐️ #FLT3_ITD #DNMT3A #WT1 and #non_ABD_NPM1 ⬇️ OS, ⬆️ relapse , ⬆️ MRD+ ⭐️ MRD- after 2 cycles is predictive of outcome ⭐️ ⬆️ salvage flag-Ida for mrd+ ⬆️OS, ⬇️ relapse Blood Journal Molecular, clinical, and therapeutic determinants of outcome in

Nice work by Abhishek Mangaonkar on lack of impact of lymphoid aggregates in patients with #MDS. Should not prevent from enrolling in trials. Mayo Clinic Comprehensive Cancer Center #MDSsm British Journal of Haematology British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

✅ multihit #STAG2 ⭐️mhSTAG2 is not common ⭐️ mhSTAG2 is subclonal ⭐️⬆️ SRSF2m 69% in mhSTAG2 ⭐️ OS is not worse with mhSTAG2 ⁦Mayo Clinic Comprehensive Cancer Center⁩ ⁦Bahga Katamesh⁩ Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience link.springer.com/article/10.100…

Look forward for this event by ⁦The Leukemia & Lymphoma Society⁩ and engaging with #Blood_Cancer 🩸#Patients in-person with great faculty in #St_Paul #Minnesota #MDS na.eventscloud.com/website/78138/…

Look forward for this event in #AZ with many great myeloid faculty from ⁦Mayo Clinic Comprehensive Cancer Center⁩ Acute and Chronic Leukemias: Practical Applications 2024 | Mayo Clinic School of Continuous Professional Development | CME Course Conference ce.mayo.edu/content/acute-…

Excited to share our review in Blood Journal !! Mark Litzow #Dr_Selina_Luger #ALL #leusm #immunotherapy Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia. ashpublications.org/blood/article-…